Darolutamide

  • TRADE NAMES: Nubeqa (Bayer); ODM-201 (Bayer)
  • INDICATIONS: Treatment of patients with non-metastatic castration-resistant prostate cancer. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
  • SYNONYM: Nubeqa
  • CLASS: Androgen receptor inhibitor
  • HALF-LIFE: 20 hours

FDA APPROVAL DATE: 07/30/2019

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

BCRP substrates, CYP3A inducers, CYP3A inhibitors


May cause fetal harm and loss of pregnancy when administered to a pregnant female. Males with female partners of reproductive potential are advised to use effective contraception during treatment and for 1 week after the last dose of darolutamide.

Our database has 12 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OTHER


Page last updated 11/11/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top